Allan NC - Search Results

1

Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.

Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: allan nc. Blood. 1996 Feb 15;87(4):1549-55. Blood. 1996. PMID: 8608246 Free article.

2

Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.

Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: allan nc. Br J Haematol. 1995 Sep;91(1):126-31. doi: 10.1111/j.1365-2141.1995.tb05257.x. Br J Haematol. 1995. PMID: 7577619

3

Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: allan nc. Blood. 2000 Jan 1;95(1):62-6. Blood. 2000. PMID: 10607685 Free article. Clinical Trial.

4

Molecular breakpoints and platelet counts in chronic myeloid leukemia.

Shepherd PC, Bond C, Allan NC. Shepherd PC, et al. Among authors: allan nc. Blood. 1992 Jul 15;80(2):556-7. Blood. 1992. PMID: 1378324 Free article. Clinical Trial. No abstract available.

5

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.

Allan NC, Richards SM, Shepherd PC. Allan NC, et al. Lancet. 1995 Jun 3;345(8962):1392-7. doi: 10.1016/s0140-6736(95)92596-1. Lancet. 1995. PMID: 7760609 Clinical Trial.

6

Progress with interferon in CML--results of the MRC UK CML III study.

Shepherd PC, Richards SM, Allan NC. Shepherd PC, et al. Among authors: allan nc. Bone Marrow Transplant. 1996 May;17 Suppl 3:S15-8. Bone Marrow Transplant. 1996. PMID: 8769693 Clinical Trial.

7

Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival.

Shepherd P, Suffolk R, Halsey J, Allan N. Shepherd P, et al. Br J Haematol. 1995 Mar;89(3):546-54. doi: 10.1111/j.1365-2141.1995.tb08362.x. Br J Haematol. 1995. PMID: 7734353 Clinical Trial.

8

Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia.

Shepherd PC, Richards S, Allan NC. Shepherd PC, et al. Among authors: allan nc. Br J Haematol. 1994 Jan;86(1):92-6. doi: 10.1111/j.1365-2141.1994.tb03257.x. Br J Haematol. 1994. PMID: 8011552

9

United Kingdom Medical Research Council Randomized Trial of Interferon Alfa in Chronic-Phase Chronic Myelogenous Leukemia.

Allan NC, Shepherd PC, Brackenridge I, Suffolk R. Allan NC, et al. Semin Hematol. 1993 Jul;30(3 Suppl 3):20-1. Semin Hematol. 1993. PMID: 8235698 Clinical Trial. No abstract available.

10

Interferon in chronic myeloid leukemia. A workshop report.

Griesshammer M, Hehlmann R, Hochhaus A, Talpaz M, Tura S, Stryckmans P, Allan NC, Tanzer J, Kolb HJ, Heimpel H. Griesshammer M, et al. Among authors: allan nc. Ann Hematol. 1993 Aug;67(2):101-6. doi: 10.1007/BF01788134. Ann Hematol. 1993. PMID: 8347729 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page